These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 26254083

  • 1. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
    Sugimoto K, Ikeya K, Iida T, Kawasaki S, Arai O, Umehara K, Watanabe F, Tani S, Oishi S, Osawa S, Yamamoto T, Hanai H.
    Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
    [Abstract] [Full Text] [Related]

  • 2. A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients.
    Veerappan SG, Healy M, Walsh B, O'Morain CA, Daly JS, Ryan BM.
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1335-44. PubMed ID: 27508327
    [Abstract] [Full Text] [Related]

  • 3. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
    Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G.
    J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
    [Abstract] [Full Text] [Related]

  • 4. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D.
    Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
    [Abstract] [Full Text] [Related]

  • 5. Serum N-terminal telopeptide of type I collagen as a biomarker for predicting bone density loss in patients with Crohn disease.
    Ishida N, Higuchi T, Miyazu T, Tamura S, Suzuki S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K.
    PLoS One; 2021 Mar; 16(4):e0250658. PubMed ID: 33905438
    [Abstract] [Full Text] [Related]

  • 6. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease.
    Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR.
    J Clin Gastroenterol; 2006 Jan; 40(1):55-63. PubMed ID: 16340635
    [Abstract] [Full Text] [Related]

  • 7. Femoral neck osteopenia in patients with inflammatory bowel disease.
    Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D.
    Am J Gastroenterol; 1998 Sep; 93(9):1483-90. PubMed ID: 9732930
    [Abstract] [Full Text] [Related]

  • 8. Association of vitamin K deficiency with bone metabolism and clinical disease activity in inflammatory bowel disease.
    Nakajima S, Iijima H, Egawa S, Shinzaki S, Kondo J, Inoue T, Hayashi Y, Ying J, Mukai A, Akasaka T, Nishida T, Kanto T, Tsujii M, Hayashi N.
    Nutrition; 2011 Oct; 27(10):1023-8. PubMed ID: 21482072
    [Abstract] [Full Text] [Related]

  • 9. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease.
    Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):607-14. PubMed ID: 15352908
    [Abstract] [Full Text] [Related]

  • 10. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
    Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z.
    Orv Hetil; 2005 Jul 10; 146(28):1477-80. PubMed ID: 16130441
    [Abstract] [Full Text] [Related]

  • 11. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis.
    Gilman J, Shanahan F, Cashman KD.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):1007-16. PubMed ID: 16573803
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D levels and bone metabolism in Chinese adult patients with inflammatory bowel disease.
    Tan B, Li P, Lv H, Li Y, Wang O, Xing XP, Qian JM.
    J Dig Dis; 2014 Mar 01; 15(3):116-23. PubMed ID: 24354597
    [Abstract] [Full Text] [Related]

  • 13. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M.
    Inflamm Bowel Dis; 2016 Dec 01; 22(12):2977-2987. PubMed ID: 27636380
    [Abstract] [Full Text] [Related]

  • 14. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Löwenberg M, Benninga MA, D'Haens GR, Kindermann A.
    Scand J Gastroenterol; 2015 Dec 01; 50(9):1110-7. PubMed ID: 25865965
    [Abstract] [Full Text] [Related]

  • 15. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
    Lacruz-Guzmán D, Torres-Moreno D, Pedrero F, Romero-Cara P, García-Tercero I, Trujillo-Santos J, Conesa-Zamora P.
    Eur J Clin Pharmacol; 2013 Mar 01; 69(3):431-8. PubMed ID: 22960943
    [Abstract] [Full Text] [Related]

  • 16. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
    Chaparro M, Barreiro-de Acosta M, Echarri A, Almendros R, Barrio J, Llao J, Gomollón F, Vera M, Cabriada JL, Guardiola J, Guerra I, Beltrán B, Roncero O, Busquets D, Taxonera C, Calvet X, Ferreiro-Iglesias R, Ollero Pena V, Bernardo D, Donday MG, Garre A, Godino A, Díaz A, Gisbert JP.
    Dig Dis Sci; 2019 Mar 01; 64(3):846-854. PubMed ID: 30426297
    [Abstract] [Full Text] [Related]

  • 17. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease.
    Schulte C, Dignass AU, Mann K, Goebell H.
    Inflamm Bowel Dis; 1998 Nov 01; 4(4):268-75. PubMed ID: 9836078
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
    Kamal ME, Werida RH, Radwan MA, Askar SR, Omran GA, El-Mohamdy MA, Hagag RS.
    Inflammopharmacology; 2024 Oct 01; 32(5):3259-3269. PubMed ID: 38985232
    [Abstract] [Full Text] [Related]

  • 19. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E, Gazouli M, Foteinogiannopoulou K, Theodoraki E, Legaki E, Romanos I, Mouzas I, Koutroubakis IE.
    Eur J Gastroenterol Hepatol; 2019 Feb 01; 31(2):187-191. PubMed ID: 30543573
    [Abstract] [Full Text] [Related]

  • 20. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study.
    Jahnsen J, Falch JA, Mowinckel P, Aadland E.
    Scand J Gastroenterol; 2004 Feb 01; 39(2):145-53. PubMed ID: 15000276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.